NeoVista announced that it will be completing the study of ROX Percutaneous Arteriovenous Fistula System (ROX AC1) by November 2010.
ROX’s minimally invasive device is designed to treat chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a lung disease in which the lungs are damaged, making it hard to breathe. In COPD, the airways or the tubes that carry air in and out of lungs are partly obstructed, making it difficult to get air in and out. ROX’s minimally invasive device has the potential to treat many patients than current lung modification strategies.
The objective of the study is to demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
The 40 patient, phase IV study is currently recruiting participants. The official title of the study is “A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)”.